clinical trial · NCT07187960
Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.·phase3·not yet recruiting·n = 228
Follicular LymphomaTQB2825 InjectionRituximab Injection
brief summary
Evaluation of the efficacy and safety of TQB2825 injection compared to immunotherapy in the treatment of recurrent/refractory follicular lymphoma.
started
Nov 1, 2025
primary completion
Oct 1, 2028
completion
Feb 1, 2029
last updated
Sep 23, 2025
official title
Randomized, Open Label, Multicenter Phase III Clinical Trial Evaluating the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Relapsed/Refractory Follicular Lymphoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol